Literature DB >> 35096402

Missing repeated measures data in clinical trials.

Stephanie L Pugh1, Paul D Brown2, Danielle Enserro3.   

Abstract

Clinical trials typically collect longitudinal data, data that are collected repeated over time, such as laboratories, scans, or patient-reported outcomes. Due to a variety of reasons, this data can be missing, whether a patient stops attending clinical visits (ie, dropout) or misses assessments intermittently. Understanding the reasons for missing data as well as predictors of missing data can aid in determination of the missing data mechanism. The analysis methods used are dependent on the missing data mechanism and may make certain assumptions about the missing data itself. Methods for nonignorable missing data, which assumes that the missing data depend on the missing data itself, make stronger assumptions and include pattern-mixture models and shared parameter models. Missing data that are ignorable after adjusting for other covariates can be analyzed using methods that adjust for covariates, such as mixed-effects models or multiple imputation. Missing data that are ignorable can be analyzed using standard approaches that require complete case data, such as change from baseline or proportion of patients who declined at a specified time point. In clinical trials, truly ignorable data are rare, resulting in additional analysis methods required for proper interpretation of the results. Conducting several analyses under different assumptions, called sensitivity analyses, can determine the extent of the impact of the missing data.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  longitudinal analysis; missing data; patient-reported outcomes

Year:  2021        PMID: 35096402      PMCID: PMC8789297          DOI: 10.1093/nop/npab043

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  17 in total

1.  Multiple imputation of missing blood pressure covariates in survival analysis.

Authors:  S van Buuren; H C Boshuizen; D L Knook
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

Review 2.  Multiple imputation: a primer.

Authors:  J L Schafer
Journal:  Stat Methods Med Res       Date:  1999-03       Impact factor: 3.021

3.  Selection models for repeated measurements with non-random dropout: an illustration of sensitivity.

Authors:  M G Kenward
Journal:  Stat Med       Date:  1998-12-15       Impact factor: 2.373

4.  Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: A practical guide.

Authors:  Suzie Cro; Tim P Morris; Michael G Kenward; James R Carpenter
Journal:  Stat Med       Date:  2020-05-17       Impact factor: 2.373

5.  Missing data methods in longitudinal studies: a review.

Authors:  Joseph G Ibrahim; Geert Molenberghs
Journal:  Test (Madr)       Date:  2009-05-01       Impact factor: 2.345

6.  Advances in analysis of longitudinal data.

Authors:  Robert D Gibbons; Donald Hedeker; Stephen DuToit
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

7.  Psychometric validation of the functional assessment of cancer therapy--brain (FACT-Br) for assessing quality of life in patients with brain metastases.

Authors:  Nemica Thavarajah; Gillian Bedard; Liying Zhang; David Cella; Jennifer L Beaumont; May Tsao; Elizabeth Barnes; Cyril Danjoux; Arjun Sahgal; Hany Soliman; Edward Chow
Journal:  Support Care Cancer       Date:  2013-11-28       Impact factor: 3.603

8.  When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts.

Authors:  Janus Christian Jakobsen; Christian Gluud; Jørn Wetterslev; Per Winkel
Journal:  BMC Med Res Methodol       Date:  2017-12-06       Impact factor: 4.615

9.  The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy.

Authors:  Nadia N Laack; Stephanie L Pugh; Paul D Brown; Sherry Fox; Jeffrey S Wefel; Christina Meyers; Ali Choucair; Deepak Khuntia; John H Suh; David Roberge; Merideth M Wendland; Deborah Bruner
Journal:  Neurooncol Pract       Date:  2018-12-03

Review 10.  Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review.

Authors:  Rebecca Mercieca-Bebber; Michael J Palmer; Michael Brundage; Melanie Calvert; Martin R Stockler; Madeleine T King
Journal:  BMJ Open       Date:  2016-06-15       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.